AR and posterior cortical atrophy: While these therapies have shown efficacy in treating AR+ CRPCa1,7, some tumors evade AR-targeted treatments by adopting alternative phenotypes, including neuroendocrine prostate cancer (NEPCa, AR−/NE+), amphicrine PCa (AR+/NE+), and double-negative PCa (AR−/NE−)8,9.